Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.
about
Inducing and Administering Tregs to Treat Human DiseaseRegulatory T cells in autoimmune neuroinflammationType 1 diabetes: translating mechanistic observations into effective clinical outcomesRegulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding TrialNOD2 regulates CXCR3-dependent CD8+ T cell accumulation in intestinal tissues with acute injury.Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model.Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetesT cells in the control of organ-specific autoimmunityThinking bedside at the bench: the NOD mouse model of T1DM.Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetesHumanized mice for immune system investigation: progress, promise and challengesTeplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.Differential response of regulatory and conventional CD4⁺ lymphocytes to CD3 engagement: clues to a possible mechanism of anti-CD3 action?Anti-CD79 antibody induces B cell anergy that protects against autoimmunity.Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus.Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.Biomarkers in type 1 diabetes: application to the clinical trial setting.Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes.Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.Intestinal Epithelial Cell Regulation of Adaptive Immune Dysfunction in Human Type 1 DiabetesCapturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.Humanized mice as a model for aberrant responses in human T cell immunotherapy.Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.Microbiota control immune regulation in humanized mice.Analysis of human biologics with a mouse skin transplant model in humanized mice.Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH
P2860
Q26772723-BAE66CF6-DED9-48A9-96CE-524A6B94AE54Q26825063-853CA8E4-538F-4769-BBE7-9BCBBB955159Q28287737-621C2FD5-C934-4F5A-9AD3-E659BF2B3F4DQ28554636-ED54D16D-2401-416D-9B55-EDAA38E6BCC3Q33782590-3BB15870-707D-49A3-A06A-A596CE10FDE8Q34375578-5C968DF9-AEC5-4FDA-AAAA-9B6F7D2880B1Q34583970-E38F0838-2448-40AE-8C58-68EAE2F6A677Q34803897-E9BB3C02-D56D-4D17-9624-76B219ACC1CEQ35360844-D01C864C-E69F-4275-9F3E-A5AF0142FC47Q35787117-EEBA171B-CACC-408B-A25E-286B9BD4DACFQ35836118-C9E4E209-CCB0-4DA7-A505-E1F55475C76CQ35911875-D8443007-724A-491B-AB6B-5FB3E5F4291FQ35976614-A6226B65-E3E5-4FE0-92E9-77CA992C8026Q36506677-063CBE3F-16D0-4121-99FC-2C58BE1B0417Q36940282-20CAE45F-A45A-4BE2-9019-EA350591A0EDQ37111994-CAD714CD-030D-4F63-A444-F982963E92D4Q37251153-4361C5CE-D739-4DE5-B5FC-0A7BCF62BA68Q37599106-51A1134B-BAE2-4E21-B548-4D66BD67694CQ37616437-A65D6B86-6DDF-4FC4-AA34-D6F430C3D653Q38071420-5451B584-39EF-4E6C-83B4-C02DEE93142FQ38187146-40A49A67-7AAC-40A1-B62B-60075C015EA5Q38220863-A5062113-D7EF-4003-B36C-FA1C25C2C21FQ38384138-1FD3B526-210C-4624-971F-DCADD58EC2B7Q38830417-7AE85026-C761-4688-8D89-E26C74FFE94EQ39001036-1DB1B639-C838-4BE4-A12A-BC3BD76ACF0CQ40080595-DCEA288F-FF0C-4DAF-A8C3-D409574A5F0FQ41816196-1B9D5357-AB80-41A4-BDEB-2A2976D0CDFEQ45066081-3826DBCC-5023-4610-9913-E59F1FB2457EQ47394131-4E57C593-1A2F-4870-9674-8BB6488E6A52Q49452941-BAFF5722-DF4F-463E-807F-38808BE4F360Q50942355-EF70C501-CE88-46EE-B731-FF26F8DC107FQ57210121-C475B475-61F8-4EB9-9672-F1384BEB946B
P2860
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.
@en
type
label
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.
@en
prefLabel
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.
@en
P2093
P2860
P1476
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients
@en
P2093
James Tooley
Kevan C Herold
Octavian Henegariu
Paula Preston-Hurlburt
Richard Flavell
Songyan Deng
P2860
P304
P356
10.1126/SCITRANSLMED.3003401
P407
P577
2012-01-01T00:00:00Z